The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Avoidable HIV infections and net health care costs would rise if coverage of pre-exposure prophylaxis (PrEP) were to be reduced even a moderate amount, according to a study published in JAMA Network ...

HIV (human immunodeficiency virus) remains a significant global health challenge, affecting millions of people worldwide. While advancements in medical science have led to better management of the ...

Friday marks the 35th anniversary of World AIDS Day, an international moment to remember, reflect and educate people on the HIV/AIDS epidemic that started over four decades ago. But due to ...

In his first term, President Trump pledged to boost HIV spending, with the lofty goal of bringing the epidemic to heel by ...

A new study found that adults in custody of the Federal Bureau of Prisons have seen improved pre-exposure prophylaxis (PrEP) initiation and sustained treatment uptake for HIV. Rates of HIV ...

Gilead's groundbreaking HIV prevention drug will soon be available at a fraction of its U.S. price in over 100 countries, ...

Lenacapavir is a long-acting HIV medication known as a capsid inhibitor. It works by blocking the virus's protective shell, ...

Pre-exposure prophylaxis (PrEP) is a medication regimen that is used to protect at-risk populations from HIV infection. The FDA approved the drug TRUVADA ...

Most transfeminine people support OTC access to PrEP for HIV prevention as means to eliminate burden and costs of clinical visits and laboratory testing.

Our society tends to think of ‘reproductive freedom’ solely in the context of the women clearly impacted by such regulations. Though, reproductive freedom legislation and regulations will ultimately ...